| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Biote Corp. Class A Common Stock$2.26
-0.01 (-0.44%)
Market Cap
62.89 M
EPS
0.86
P/E Ratio
2.1 $
Value Trade
405.62 K
SEC Financials
Q1 2026Dilution Risk
Revenue
44.94 M
Operating CF
3.90 M
Total Assets
89.03 M
Total Liabilities
136.99 M
Equity
-56.09 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
5.32 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
160.93 K
52 Week Range
1.27 - 4.75
% held by Insiders
9.39 %
% held by Institutions
65.94 %
Enterprise Value
175.33 M
Total Shares
32.24 M
Short %
9.45 %
Float Shares
14.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BTMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BTMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BTMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BTMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BTMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BTMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BTMD
Jun 1, 2026Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Biote has announced the appointment of Komal Bajaj, MD, MS as its new Chief Medical Officer. This leadership change is part of the company's strategy to enhance its medical expertise. Dr. Bajaj brings significant experience in the biopharma sector to her new role.
Read more →-BTMD
May 28, 2026Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
Biote has appointed Bob Peterson, the current Chief Financial and Chief Business Officer, as the Interim CEO. This leadership change comes as the company seeks to navigate its strategic direction. Further details regarding the transition and its implications for the company have not been disclosed.
Read more →-BTMD
May 6, 2026Biote Reports First Quarter 2026 Financial Results
Biote has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. Specific details regarding revenue, expenses, and other financial metrics were not disclosed in the text provided.
Read more →-BTMD
Apr 22, 2026Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
Biote has announced the scheduling of its financial results release for the first quarter of 2026, along with a conference call to discuss these results. This event aims to provide stakeholders with insights into the company's financial performance and future outlook. Further details regarding the call will be shared closer to the date.
Read more →-BTMD
Feb 26, 2026Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
Biote Corp. has announced the release date for its fourth quarter and full year financial results, scheduled for March 11, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results. The company emphasizes its commitment to hormone replacement therapy and healthy aging solutions, showcasing its innovative approach in the healthcare sector.
Read more →Competitive Position
How BTMD ranks across every disease it competes inCompetitive Position is a premium feature
See how BTMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial